Late breaking articles

• Resistance & Resistance Testing in Chronic Treatment-Naïve & Acute HIV
       Reported by Jules Levin (3/16/2001)
  
  

• High Risk Behavior/Attitudes For Acquiring HIV Infection
  Exposure to a Person Experiencing Acute HIV May Present High Risk for Getting Infected; Misconceptions about HIV Treatment Among Uninfected
        Reported for NATAP by Harvey Bartnoff, MD
  
  

• Expert Advice Matters When Interpreting Resistance Testing
       Reported by Jules Levin (3/14/2001)
  

• Lipodystrophy May Be Related to Cortisol: DHEA Ratio and Serum Alpha-Interferon
       Reported for NATAP by Harvey Bartnof, MD (3/14/2001)
  
  

• Study Suggests Potent HAART & Intensification May Prevent Viral Rebound
       Reported by Jules Levin (3/12/2001)
  
  

• This Study Suggests Viral Load Blips Matter
       Reported by Jules Levin
  Study Finds That The Risk of Viral Failure (>500 copies/ml) Increases with Repeated Viral Load Values Between 51-500 (after repeatedly being below 50 copies/ml), and Risk Increases When Last Value Was 300-500 (3/12/2001)
  
  

• Lipodystrophy Following HAART in Acute HIV: Study Finds Better Response to HAART May Be Associated With Lipodystrophy
       Reported by Jules Levin (3/12/2001)
  
  

• Women in HIV: Highlights from the 8th Annual Retrovirus Conference
  (simpler easier-to-read version)
       Written for NATAP by Kathleen Squires, MD, Medical Director of the University of Southern California HIV Clinic, Los Angeles, CA; edited by Jules Levin, NATAP (3/07/2001)
  
  

• HIV Infection in Women
        Reported for NATAP by Kathleen Squires, MD, Director of the University of Southern California HIV Clinic & Research (3/05/2001)
  
  

• Hepatitis Virus Infections, Including HIV Co-Infection Part III:
  6%-20% of HCV/HIV coinfected found to have false HCV negativity, may be related to low CD4 count; HBV false negatives also seen
       By Harvey S. Bartnof, MD (3/01/2001)
  
  

• Is There a Genetic Predisposition To Responding Better To Therapy? Maybe
       Reported by Jules Levin
  &....
  Predictive Power of P- Glycoprotein and CYP2D6 Polymorphisms for Plasma Levels of Antiretroviral Agents (3/01/2001)
  
  

• Should You Test Your Lactate Levels??
  Hyperlactatemia in HIV-Infected Patients: The Role of NRTI Treatment (2/27/2001)
  
  

• Highlights about Treatment Interruptions in HIV/AIDS
       By Harvey S. Bartnof, MD (2/26/2001)
  
  

• HIV and Hepatitis Virus Co-infection: The Center of Two Epidemics
     Part I:
       By Nancy Shulman, MD, Stanford University School of Medicine. Edited by Harvey S. Bartnof, MD, Staff Physician at the AIDS Virus Education and Research Institute (AVERI) in San Francisco
     Part II:
       By Jules Levin, Edited by Harvey S. Bartnof, MD (2/26/2001)
  
  

• An Assessment of Lipodystrophy in Patients Receiving AZT or D4T regimen After Receiving AZT, DDI and/or DDC
        Reported by Jules Levin (2/26/2001)
  
  

• Risky Sex Practices That May Increase Risk for Getting HCV Among Men Who Have Sex With Men (2/26/2001)
  
  

• MACS Database on Lipodystrophy: prevalence of body changes & lab abnormalities (lipids, sugar)
       L. Kingsley from the University of Pittsburgh (2/26/2001)
  
  

• Retrovirus Study Suggests Asociation Between Lower Body weight or Body Mass & Abacavir Hypersensitivity Reaction (2/26/2001)
  
  

• What Is Risk For Increased Heart Disease From HAART? (2/22/2001)
       and...

• Update From Retrovirus on Switching Studies
       Reported by Jules Levin & Gilbert Kaufman, MD, Univ Hosp Basel, Switzerland
  Selected reports from the Conference that are of interest...(2/22/2001)
  
  

  Insulin Resistance, Lipodtstrophy & Decreased Body Mass Occurred More Often in HCV/HIV Coinfected than in HIV-infected in This Study
  --Better Research Needed (2/22/2001)
  
  

• Pharmacology Review of the 8th CROI: Therapeutic Drug Monitoring
       Written for NATAP by Stephen C. Piscitelli, PharmD (2/21/2001)
  
  

• Selected Highlights on HIV Transmission, Women & Children: HAART reduces perinatal transmission (2/19/2001)
  
  

• Efavirenz 006 Analysis of Virologic Failures Only:
  2-3 YEAR FOLLOW-UP
  When To Begin Therapy Analysis Suggests Baseline CD4 Count Does Matter (2/19/2001)
  
  

• Transmission From Mother to Newborn is Preventable if Viral Load is <1000 copies/ml at Delivery (1%) (2/19/2001)
  
  

• HAART has a beneficial effect for women with HIV with Cervical Intraepithelial Neoplasia (CIN) (2/19/2001)
  
  

• Alarming HIV Prevalence Among African American MSM
       In New York City (542 men surveyed) (2/19/2001)
  
  

• Garlic & Marijuana Interactions with HIV Drugs  (2/16/2001)
  
  

• Immunology -- IL-2, CD4 changes during STI, CTLs, Chemokins receptors
    (2/16/2001)
       and...

• Viral Reservoirs (latency/persistance): blind men describing an elephant
       Written for NATAP by David Margolis, MD, Associate Professor, University of Texas Southwestern Medical Center  (2/16/2001)
  
  

• 8th CROI: Review of HIV Resistance and Resistance Testing
       Andrew Zolopa, MD, Stanford University  (2/16/2001)
  
  

• HIV-Related Cancers: Waiting (and Waiting) for the Storm  (2/16/2001)
      and...

• Opportunistic Infections: Down and Out in London, Paris and New York
  (but not in Harare, Jo'berg or Kinshasa)
       David Alain Wohl, MD - Clinical Assistant Professor, The University of North Carolina  (2/16/2001)
  
  

• Differentiating within and between drug classes: sometimes it's toxicity, sometimes its efficacy--efficacy of new EC ddI formulation, 2 yr follow-up on
  efavirenz, once daily 3TC vs FTC, NNRTIs in EuroSida database, Kaletra in
  treatment-naive
  
       Written for NATAP by Dr Graeme Moyle MD MBBS, Chelsea and Westminster Hospital, London UK  (2/16/2001)
  
  

• Women and Clinical Trials  (2/16/2001)
      and...

• The HIV-Positive Women:н Are You Getting Good Medical Care?
  нннн Debra Johnson, NP, PA-C & Kathleen E. Squires, MD  (2/16/2001)
  
  

• Women and Children Get HIV Also!
       Judith A. Aberg, M.D., Medical Director, HIV Services, Washington University School of Medicine, AIDS Clinical Trials Unit  (2/16/2001)
  
  

• Highlights on Lipodystrophy (Fat Redistribution) and Adverse Effects of Anti-HIV Drugs
  (This is a preliminary report on Lipodystrophy. A more detailed report will follow)
       Written for NATAP by Dr. Gilbert Kaufmann, Med. Poliklinik, University Hospital Basel, Petersgraben Switzerland  (2/16/2001)
  
  

• T-20 and Beyond: "Entry Inhibitors" at the 8th CROI  (2/16/2001)
      and...
• Primary HIV Infection: Resistance, Treatment and Transmission issues
       Reported for NATAP by Christopher D. Pilcher, M.D. of the UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (2/14/2001)
  
  
• Neurologic Complications of HIV Infection - From Head to Toe: risk factors include viral load, cd4s
       Written for NATAP by David Alain Wohl, MD, Clinical Assistant Professor, University of North Carolina School of Medicine (2/14/2001)
  
  

• New Drugs Reported at Retrovirus
       Reported for NATAP by Nancy Shulman, MD, Asst Prof of Medicine at Stanford University, Palo Alto, California (2/13/2001)
  

• Strategic Treatment Interruptions in Primary and Chronic HIV infection
       Reported by Christopher D. Pilcher, M.D. of the UNC Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (2/12/2001)
  
  

• When To Begin Studies Reported at Retrovirus Conference
  - Brief Summary of Opravil Study
  - Clinical Benefit of Early Initiation of HAART in Patients with Asymptomatic HIV Infection and CD4s >350
  - CD4 Lymphocyte Count Level is Better than HIV-1 Plasma Viral Load in Determining When to Initiate HAART
  - Late Initiation of Antiretroviral Therapy (at CD4 count <200) is Associated with Increased Risk of Death
    (2/10/2001, rev. 2/19/2001)
  

• CCR5-D32 Mutation -- Protective Against HIV, but Bad for Hepatitis C Virus? (Abstract 499)
       Institute of Experimental Hematology, Virology, Univ. of Bonn, Germany (2/10/2001)
  also on this page...
  Mutation That Slows HIV May Play a Role in Hepatitis C
       New York Times - February 7, 2001 (2/10/2001)
  

• Combining Interferon + Ribiviran with DDI for Anti-HIV & HCV Activity
  A Highly Synergistic Tripe Antiviral Combination with Potential Activity against Both HIV and Hepatitis C Viruses (2/9/2001)
  

• Hope From This Year's 8th Retrovirus Conference: new drugs in development
       Reported by Jules Levin
  also on this page
  ACH-126,443: new NRTI that may not cause or might reverse mitochondrial activity, may be active against HIV resistant virus and has 24 hour intracellular half-life
       Reported by Jules Levin
  (2/8/2001)

• FTC vs 3TC Once Daily
       Reported by Jules Levin
  (2/8/2001)
  
  

• Kaletra in PI Experienced; Liver Transplants; New Entry Inhibitor in Early Development
       Reported by Jules Levin
  (2/8/2001)
  
  

• Adverse events--neuropathy & lipodystrophy in primary infection: Summary of presentations on lipodystrophy and adverse events
       Dr. Gilbert Kaufmann, Med. Poliklinik, University Hospital Basel, Petersgraben, Switzerland
  (2/7/2001)
  
  

• HIV-Related Peripheral Neuropathy and Their Treatment
       Lactate Concentrations Distinguish Between Nucleoside Neuropathy and HIV Distal Symmetrical Sensory Polyneuropathy
  (2/7/2001)

• Highlights From the Conference - Peripheral Neuropathy and more  
  (2/6/2001)
  
  

• Report 1 -
  Opening Session
  A Call To Arms To Implement A Program Suggested by Sachs to Provide HAART To Africa & The Developing World: which organizations & individuals are willing to undertake this initiative described below
  (2/5/2001)
  
  

• Report 2 -
  Avoidance of Antibody Recognition by SIV- and HIV-Encoded Envelope Proteins
       Bernard Fields Memorial Lecture
       Ronald Desrosiers
       Harvard Med. School, New England Regional Primate Research Center, Southborough, MA
  (2/5/2001)
  

• Report 3 -
  
  New agents promise tempered with caution on side effects, pharmacology and resistance: Antiviral Chemotherapy session 1
       Written for NATAP by Graeme Moyle MD, MBBS. Chelsea and Westminster Hospital London UK
  (2/6/2001)